DE60130798D1 - "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus " - Google Patents
"alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus "Info
- Publication number
- DE60130798D1 DE60130798D1 DE60130798T DE60130798T DE60130798D1 DE 60130798 D1 DE60130798 D1 DE 60130798D1 DE 60130798 T DE60130798 T DE 60130798T DE 60130798 T DE60130798 T DE 60130798T DE 60130798 D1 DE60130798 D1 DE 60130798D1
- Authority
- DE
- Germany
- Prior art keywords
- polypeptides
- epilepsia
- generalized
- substance
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 3
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 abstract 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 abstract 1
- 102220478897 Sodium channel protein type 1 subunit alpha_I1656M_mutation Human genes 0.000 abstract 1
- 102220478845 Sodium channel protein type 1 subunit alpha_V1353L_mutation Human genes 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 102200072280 rs121917953 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR2203A AUPR220300A0 (en) | 2000-12-20 | 2000-12-20 | New epilepsy gene |
PCT/AU2001/001648 WO2002050096A1 (en) | 2000-12-20 | 2001-12-20 | Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60130798D1 true DE60130798D1 (de) | 2007-11-15 |
Family
ID=3826237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60130798T Expired - Lifetime DE60130798D1 (de) | 2000-12-20 | 2001-12-20 | "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus " |
Country Status (9)
Country | Link |
---|---|
US (1) | US7078515B2 (de) |
EP (2) | EP1837342A3 (de) |
JP (1) | JP4204317B2 (de) |
AT (1) | ATE374783T1 (de) |
AU (1) | AUPR220300A0 (de) |
CA (2) | CA2431891C (de) |
DE (1) | DE60130798D1 (de) |
NZ (2) | NZ541915A (de) |
WO (1) | WO2002050096A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1252330T1 (de) * | 1999-11-26 | 2003-11-27 | Univ Montreal Mcgill | Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie |
AU2003904154A0 (en) * | 2003-08-07 | 2003-08-21 | Bionomics Limited | Mutations in ion channels |
NZ530258A (en) | 2001-07-18 | 2006-01-27 | Bionomics Ltd | Mutations in SCN1A SCN2A SCN3A SCN8A sodium ion channels and their use in diagnosing epilepsy |
US7709225B2 (en) * | 2001-07-18 | 2010-05-04 | Bionomics Limited | Nucleic acids encoding mutations in sodium channels related to epilepsy |
US7282336B2 (en) * | 2001-07-18 | 2007-10-16 | Bionomics Limited | Method of diagnosing epilepsy |
CA2474751A1 (en) | 2002-02-25 | 2003-09-04 | Vanderbilt University | Expression system for human brain-specific voltage-gated sodium channel, type 1 |
AU2003901425A0 (en) * | 2003-03-27 | 2003-04-10 | Bionomics Limited | A diagnostic method for epilepsy |
AU2004263548B2 (en) * | 2003-08-07 | 2007-09-13 | Bionomics Limited | Mutations in ion channels |
CA2612180A1 (en) * | 2005-06-16 | 2006-12-21 | Bionomics Limited | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
CN101229184B (zh) * | 2008-01-17 | 2010-08-11 | 周锡漳 | 一种脱氧核糖核酸降解片段复合物及其制备药物的应用 |
CN101229183B (zh) * | 2008-01-17 | 2010-11-24 | 周锡漳 | 一种核糖核酸降解片断复合物及其应用 |
US20120283116A1 (en) | 2009-09-11 | 2012-11-08 | Leppert Mark F | Mutant Sodium Channel Nav1.7 and Methods Related Thereto |
EP2770325A1 (de) | 2013-02-26 | 2014-08-27 | Institut du Cerveau et de la Moelle Epiniere-ICM | Mutationen von DEPDC5 zur Diagnose von epileptischen Funktionsstörungen, Erkrankungen oder Leiden |
EP3528807A4 (de) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | Verfahren zur behandlung von entwicklungsstörungen und/oder von anfällen mit flupirtin |
CN114957445B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1252330T1 (de) * | 1999-11-26 | 2003-11-27 | Univ Montreal Mcgill | Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie |
AU2002351175A1 (en) * | 2001-11-26 | 2003-06-10 | Bristol-Myers Squibb Company | Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof |
AU2003901425A0 (en) | 2003-03-27 | 2003-04-10 | Bionomics Limited | A diagnostic method for epilepsy |
-
2000
- 2000-12-20 AU AUPR2203A patent/AUPR220300A0/en not_active Abandoned
-
2001
- 2001-12-20 EP EP07075396A patent/EP1837342A3/de not_active Withdrawn
- 2001-12-20 DE DE60130798T patent/DE60130798D1/de not_active Expired - Lifetime
- 2001-12-20 JP JP2002551989A patent/JP4204317B2/ja not_active Expired - Lifetime
- 2001-12-20 EP EP01271383A patent/EP1351968B1/de not_active Expired - Lifetime
- 2001-12-20 CA CA2431891A patent/CA2431891C/en not_active Expired - Lifetime
- 2001-12-20 CA CA2714357A patent/CA2714357C/en not_active Expired - Lifetime
- 2001-12-20 NZ NZ541915A patent/NZ541915A/en not_active IP Right Cessation
- 2001-12-20 WO PCT/AU2001/001648 patent/WO2002050096A1/en active IP Right Grant
- 2001-12-20 NZ NZ526814A patent/NZ526814A/en not_active IP Right Cessation
- 2001-12-20 AT AT01271383T patent/ATE374783T1/de not_active IP Right Cessation
- 2001-12-20 US US10/451,126 patent/US7078515B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE374783T1 (de) | 2007-10-15 |
EP1837342A2 (de) | 2007-09-26 |
CA2714357A1 (en) | 2002-06-27 |
EP1351968A1 (de) | 2003-10-15 |
US20040110706A1 (en) | 2004-06-10 |
JP4204317B2 (ja) | 2009-01-07 |
CA2431891A1 (en) | 2002-06-27 |
EP1837342A3 (de) | 2007-12-19 |
NZ541915A (en) | 2007-05-31 |
JP2004515252A (ja) | 2004-05-27 |
US7078515B2 (en) | 2006-07-18 |
EP1351968A4 (de) | 2004-04-28 |
CA2714357C (en) | 2013-11-12 |
WO2002050096A1 (en) | 2002-06-27 |
CA2431891C (en) | 2013-01-29 |
EP1351968B1 (de) | 2007-10-03 |
AUPR220300A0 (en) | 2001-01-25 |
NZ526814A (en) | 2006-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60130798D1 (de) | "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus " | |
DK0927024T3 (da) | Indretning og fremgangsmåde til behandling af öjensygdomme | |
PL397846A1 (pl) | Leczenie zaburzeń związanych z TNFα | |
DE69906671D1 (de) | Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen | |
CY1112845T1 (el) | Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α | |
ATE515513T1 (de) | Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten | |
DE602004024836D1 (de) | Behandlung neurologischer und neuropsychiatrischer Erkrankungen mit Botulinumtoxin | |
MXPA02001911A (es) | Anticuerpos ctla-4 humanos y sus usos. | |
DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
BRPI0313792B8 (pt) | utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
ATE226947T1 (de) | 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung | |
ATE500328T1 (de) | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion | |
TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
DE68925004D1 (de) | Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen. | |
DE69524623D1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE485377T1 (de) | Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen | |
ATE222491T1 (de) | Melatonin-derivate zur verwendung in der behandlung von schlafstörungen | |
DK0602172T3 (da) | Metode til behandling af patienter med kronisk leversygdom | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
GR3036049T3 (en) | Composition for use in the treatment of tumours and the immunization of humans and animals. | |
DE60024969D1 (de) | 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten | |
DE69823191D1 (de) | 1,2,3-thiadiazol-derivate, mittel zur kontrolle von pflanzenkrankheiten und methode zu seiner anwendung | |
DK1133297T3 (da) | Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin | |
FR2816633B1 (fr) | Methode de criblage d'agents susceptibles de traiter l'obesite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |